168 related articles for article (PubMed ID: 27220665)
1. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M
Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665
[No Abstract] [Full Text] [Related]
2. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Strati P; Schlette EJ; Solis Soto LM; Duenas DE; Sivina M; Kim E; Keating MJ; Wierda WG; Ferrajoli A; Kantarjian H; Estrov Z; Jain N; Thompson PA; Wistuba II; Burger JA
Blood; 2020 Feb; 135(7):510-513. PubMed ID: 31895947
[No Abstract] [Full Text] [Related]
3. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
[TBL] [Abstract][Full Text] [Related]
4. Haematological cancer: Ibrutinib supercharges CAR T cells.
Sidaway P
Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26880473
[No Abstract] [Full Text] [Related]
5. [Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
Nakamura M; Yoshioka S; Yamashita D; Hara S; Ishikawa T
Rinsho Ketsueki; 2019; 60(10):1449-1454. PubMed ID: 31695006
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Albi E; Baldoni S; Aureli P; Dorillo E; Del Papa B; Ascani S; Di Ianni M; Falzetti F; Sportoletti P
Tumori; 2017 Nov; 103(Suppl. 1):e37-e40. PubMed ID: 28708231
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Gohil SH; Evans R; Harasser M; El-Kholy M; Paredes-Moscosso SR; Della Peruta M; Nathwani AC
Br J Haematol; 2019 Jul; 186(2):380-382. PubMed ID: 30957227
[No Abstract] [Full Text] [Related]
8. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2018 Dec; 59(12):2792-2800. PubMed ID: 29764250
[TBL] [Abstract][Full Text] [Related]
9. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
10. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
[No Abstract] [Full Text] [Related]
11. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
12. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Robier C; Beham-Schmid C; Neubauer M
Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
[No Abstract] [Full Text] [Related]
13. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Shumilov E; Wulf G; Ströbel P; Hasenkamp J; Hellige N; Bleckmann A; Haase D; Braulke F; Jung W; Schanz J; Binder M; Trümper L; Bacher U
Leuk Lymphoma; 2016 Oct; 57(10):2476-80. PubMed ID: 26916814
[No Abstract] [Full Text] [Related]
14. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Molica S; Polliack A
Leuk Res; 2016 Nov; 50():31-36. PubMed ID: 27657651
[TBL] [Abstract][Full Text] [Related]
15. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
16. [Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
Zhang H; Zhang XH; Chen P; Li BZ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):428-430. PubMed ID: 32536143
[No Abstract] [Full Text] [Related]
17. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
18. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Williams AM; Baran AM; Schaffer M; Bushart J; Rich L; Moore J; Barr PM; Zent CS
Am J Hematol; 2020 Jan; 95(1):E16-E18. PubMed ID: 31621100
[No Abstract] [Full Text] [Related]
19. [Immunological profile of lymphoid cells in patients with chronic lymphoid leukemia and immunological complications during the treatment with prednisolone and chlorambucil].
Lohins'kyĭ VO; Karol' IuS; Tsiapka OM; Vyhovs'ka IaI
Lik Sprava; 2009; (1-2):44-9. PubMed ID: 19953990
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
